- $993.55m
- $1.38bn
- $463.40m
NYSE ORDER IMBALANCE 186401.0 SHARES ON BUY SIDE
NYSE ORDER IMBALANCE 84332.0 SHARES ON SELL SIDE
NYSE ORDER IMBALANCE 87539.0 SHARES ON SELL SIDE
NYSE ORDER IMBALANCE 89037.0 SHARES ON SELL SIDE
NYSE ORDER IMBALANCE 73784.0 SHARES ON SELL SIDE
NYSE ORDER IMBALANCE 70062.0 SHARES ON SELL SIDE
Brief: Emerald Holding To Receive $400 Mln Convertible Preferred Stock Infusion Led By Onex
NYSE ORDER IMBALANCE 157422.0 SHARES ON SELL SIDE
U.S. RESEARCH ROUNDUP-Alexander's, Ferrari, Stemline Therapeutics
Brief: Emerald Expositions Events - Former CEO Sally Shankland Passed Away On After A Previously Disclosed Illness
Brief: Emerald Holding Says Ended Q1 Of 2020 With $50 Mln In Cash And Total Liquidity Of $150 Mln
Brief: Emerald Holding Announces Temporary Suspension Of Quarterly Dividend
Brief: Emerald Holding Announces Update Regarding Impact Of Coronavirus
NYSE ORDER IMBALANCE 248068.0 SHARES ON SELL SIDE
NYSE ORDER IMBALANCE 248068.0 SHARES ON SELL SIDE
Brief: Emerald Reports Fiscal 2019 Financial Results
Brief: Emerald Expositions Names David Doft Incoming CFO
Brief: Emerald Expositions SALLY SHANKLAND TO STEP DOWN FROM HER POSITION AS PRESIDENT AND CEO AT END OF YEAR
Brief: Emerald Expositions Reports 26.7% Q3 Revenue Decline